Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$100.90+0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MIRM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | 618.1 | 521.3 | 336.9 | 186.4 | 77.1 | 19.1 | 0.0 | — |
| Total Revenues | — | — | — | — | — | 19.1 | 0.0 | — |
| Operating Expenses & Income | ||||||||
| Selling, General & Admin | 313.8 | 257.0 | 202.2 | 145.9 | 89.1 | 59.2 | — | — |
| Operating Income | (834.0) | (22.1) | (87.6) | (109.2) | (131.2) | (173.4) | (104.3) | (54.7) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | 14.4 | 14.3 | — | — | — | — | — |
| Interest & Investment Income | 13.9 | 12.7 | 13.8 | 13.7 | 3.9 | 0.4 | 1.6 | 2.2 |
| EBT, Incl. Unusual Items | (857.5) | (21.4) | (86.9) | (162.4) | (142.1) | (84.0) | (103.3) | (52.5) |
| Income Tax Expense | 2.7 | 1.9 | 1.0 | 1.0 | (6.4) | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||
| Net Income | (860.2) | (23.4) | (87.9) | (163.4) | (135.7) | (84.0) | (103.3) | (52.6) |
| Per Share | ||||||||
| Basic EPS | (13.57) | (0.47) | (1.85) | (4.00) | (4.01) | (2.77) | — | — |
| Diluted EPS | (13.57) | (0.47) | (1.85) | (4.00) | (4.02) | (2.77) | — | — |
| Revenue per Share | 9.75 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 63.4 | 50.2 | 47.5 | 40.9 | 33.8 | 30.3 | — | — |
| Diluted Weighted Avg Shares | 63.4 | 50.2 | 47.5 | 40.9 | 34.0 | 30.3 | — | — |
| Supplemental | ||||||||
| EBITDA | — | 2.1 | (64.0) | (98.3) | (128.0) | (172.8) | (104.0) | (54.6) |
| EBIT | (834.0) | (22.1) | (87.6) | (109.2) | (131.2) | (173.4) | (104.3) | (54.7) |
| Effective Tax Rate | -0.3% | — | — | -0.6% | 4.5% | -0.0% | -0.0% | -0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.